Public Employees Retirement System of Ohio Sells 7,045 Shares of Illumina, Inc. (NASDAQ:ILMN)

Public Employees Retirement System of Ohio decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.8% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,820 shares of the life sciences company’s stock after selling 7,045 shares during the period. Public Employees Retirement System of Ohio’s holdings in Illumina were worth $8,901,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Bouvel Investment Partners LLC grew its holdings in shares of Illumina by 1.3% in the first quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock worth $899,000 after purchasing an additional 84 shares during the last quarter. STF Management LP grew its holdings in shares of Illumina by 3.5% in the fourth quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock worth $368,000 after purchasing an additional 90 shares during the last quarter. Global Retirement Partners LLC grew its holdings in shares of Illumina by 12.3% in the first quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock worth $118,000 after purchasing an additional 94 shares during the last quarter. Gulf International Bank UK Ltd grew its holdings in shares of Illumina by 0.7% in the first quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock worth $1,862,000 after purchasing an additional 98 shares during the last quarter. Finally, Clear Creek Financial Management LLC grew its holdings in shares of Illumina by 6.3% in the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock worth $236,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ILMN. Scotiabank cut their price target on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating on the stock in a report on Monday, May 6th. TD Cowen lowered their price objective on shares of Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research note on Thursday, June 6th. Jefferies Financial Group began coverage on shares of Illumina in a research note on Monday, June 3rd. They issued a “hold” rating and a $115.00 price objective for the company. Barclays increased their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. Finally, Royal Bank of Canada decreased their price target on shares of Illumina from $249.00 to $242.00 and set an “outperform” rating for the company in a research report on Monday, July 1st. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $158.57.

Illumina Stock Performance

Shares of NASDAQ ILMN traded up $1.13 during midday trading on Monday, reaching $121.56. 1,097,577 shares of the stock were exchanged, compared to its average volume of 2,125,137. The firm has a market cap of $19.36 billion, a price-to-earnings ratio of -14.78 and a beta of 1.15. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $195.64. The firm has a 50-day simple moving average of $109.87 and a two-hundred day simple moving average of $124.08. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter last year, the firm posted $0.08 EPS. The business’s revenue was down 1.0% on a year-over-year basis. As a group, analysts anticipate that Illumina, Inc. will post 1.38 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.